SHPH Overview

CFO Resignation: Timothy Lorber has resigned as Chief Financial Officer of Shuttle Pharmaceuticals Holdings, Inc. effective November 21, 2025.

Interim CFO Appointment: Christopher Cooper, the current Interim Chief Executive Officer, has taken over the role of Chief Financial Officer.

Search for Permanent CFO: The company is actively searching for a permanent Chief Financial Officer to fill the position.

Disclaimer: The views expressed in the article do not necessarily reflect those of Nasdaq, Inc.

LexinFintech Holdings Performance: LexinFintech Holdings Ltd reported a significant increase in quarterly earnings, rising to 43 cents per share from 28 cents a year ago, despite a drop in sales to $367.580 million from $521.851 million. The stock surged 15.3% in pre-market trading.

Other Gainers in Pre-Market Trading: Several stocks saw notable increases in pre-market trading, including Inspire Veterinary Partners Inc (+54.4%), VisionSys AI Inc (+43.4%), and JX Luxventure Group Inc (+36.2%).

Losers in Pre-Market Trading: Conversely, stocks like Clearside Biomedical Inc (-50.3%), Shuttle Pharmaceuticals Holdings Inc (-15%), and XChange TEC.INC (-14%) experienced significant declines in pre-market trading.

Market Overview: The article provides a snapshot of various stocks' performances in pre-market trading, highlighting both gainers and losers, along with specific percentage changes.

Stock Performance: Shuttle Pharmaceuticals Holdings Inc. (SHPH) saw a 27.87% increase in after-hours trading, reaching $2.34, despite closing down 7.58% at $1.83 during regular trading. The stock is down 91.4% year-to-date.

S-1 Registration Statement: The company filed a Form S-1 registration statement with the SEC for the resale of 625,156 common shares linked to a pre-funded warrant with a $0.001 exercise price.

Private Placement: Shuttle Pharmaceuticals completed a private placement on November 4, generating approximately $2.5 million in gross proceeds from an accredited investor, with WestPark Capital Inc. acting as the placement agent.

Market Capitalization: As of Monday, the company had 1,603,285 outstanding shares and a market capitalization of $2.93 million, with the filing indicating that it will not receive proceeds from the selling stockholder’s share sales.

Acquisition Announcement: Shuttle Pharmaceuticals Holdings, Inc. has signed a non-binding letter of intent to acquire Molecule.ai for $10 million, contingent on certain milestones and final terms.

Strategic Goals: The acquisition aims to enhance Shuttle's drug discovery capabilities through Molecule.ai's AI platform, while Shuttle maintains a strong financial position to support the deal.